{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:58:08Z","timestamp":1776376688701,"version":"3.51.2"},"reference-count":135,"publisher":"Elsevier","isbn-type":[{"value":"9780443295485","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025157","name":"CSIR-Indian Institute of Toxicology Research, Government of India","doi-asserted-by":"publisher","award":["IITR\/SECC-PME\/MSS\/2025\/015"],"award-info":[{"award-number":["IITR\/SECC-PME\/MSS\/2025\/015"]}],"id":[{"id":"10.13039\/501100025157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.vh.2025.04.001","type":"book-chapter","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:55:27Z","timestamp":1745844927000},"page":"143-183","source":"Crossref","is-referenced-by-count":1,"title":["Targeting epigenetic effects of androgen-androgen receptor signaling in prostate cancer"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1139\/bcb-2015-0038","article-title":"Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines","volume":"94","author":"Abbas","year":"2016","journal-title":"Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/biomedicines11020633","article-title":"Oncogenic long noncoding RNAs in prostate cancer, Osteosarcoma, and metastasis","volume":"11","author":"Al-Shehri","year":"2023","journal-title":"Biomedicines"},{"issue":"7006","key":"10.1016\/bs.vh.2025.04.001_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/pros.20376","article-title":"NF-kappaB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells","volume":"66","author":"Armstrong","year":"2006","journal-title":"The Prostate"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 Loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Research"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ctrv.2013.05.009","article-title":"The promise and failures of epigenetic therapies for cancer treatment","volume":"40","author":"Bojang","year":"2014","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/bs.vh.2025.04.001_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.phrs.2016.10.021","article-title":"Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells","volume":"114","author":"Boyanapalli","year":"2016","journal-title":"Pharmacological Research"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-023-36253-1","article-title":"Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Nature Communications"},{"issue":"33","key":"10.1016\/bs.vh.2025.04.001_bib12","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1073\/pnas.1107898108","article-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","volume":"108","author":"Chang","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.24479","article-title":"Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH","volume":"83","author":"Chang","year":"2023","journal-title":"The Prostate"},{"issue":"9","key":"10.1016\/bs.vh.2025.04.001_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-04-0287","article-title":"Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824","volume":"4","author":"Chen","year":"2005","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BJ20100980","article-title":"Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor","volume":"433","author":"Choi","year":"2011","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1349-7006.2010.01737.x","article-title":"Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility","volume":"102","author":"Chung","year":"2011","journal-title":"Cancer Science"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib17","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: Current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib19","first-page":"3","article-title":"Androgen receptor structure, function and biology: From bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"The Clinical Biochemist. Reviews"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jcb.20794","article-title":"Molecular regulation of androgen action in prostate cancer","volume":"99","author":"Dehm","year":"2006","journal-title":"Journal of Cellular Biochemistry"},{"issue":"12","key":"10.1016\/bs.vh.2025.04.001_bib22","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1210\/me.2007-0223","article-title":"Androgen receptor structural and functional elements: Role and regulation in prostate cancer","volume":"21","author":"Dehm","year":"2007","journal-title":"Molecular Endocrinology (Baltimore, Md.)"},{"issue":"8","key":"10.1016\/bs.vh.2025.04.001_bib23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mnfr.201100141","article-title":"Resveratrol and prostate cancer: Promising role for microRNAs","volume":"55","author":"Dhar","year":"2011","journal-title":"Molecular Nutrition & Food Research"},{"issue":"29","key":"10.1016\/bs.vh.2025.04.001_bib24","doi-asserted-by":"crossref","first-page":"27214","DOI":"10.18632\/oncotarget.4877","article-title":"Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer","volume":"6","author":"Dhar","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10637-015-0252-4","article-title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","volume":"33","author":"Eigl","year":"2015","journal-title":"Investigational New Drugs"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2007.51","article-title":"Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: A randomized controlled trial","volume":"299","author":"Emmelot-Vonk","year":"2008","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/jcm8040442","article-title":"NCL1, a highly selective lysine-specific demethylase 1 Inhibitor, suppresses castration-resistant prostate cancer growth via regulation of apoptosis and autophagy","volume":"8","author":"Etani","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"22","key":"10.1016\/bs.vh.2025.04.001_bib28","first-page":"7563","article-title":"Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines","volume":"63","author":"Fang","year":"2003","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1677\/ERC-08-0130","article-title":"Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models","volume":"16","author":"Festuccia","year":"2009","journal-title":"Endocrine-Related Cancer"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib30","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3892\/or.2016.5000","article-title":"Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5\u2019-Aza-2\u2019-deoxycytidine","volume":"36","author":"Fialova","year":"2016","journal-title":"Oncology Reports"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.bjc.6602030","article-title":"Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation","volume":"91","author":"Florl","year":"2004","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib32","first-page":"111","article-title":"Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells","volume":"39","author":"Fortson","year":"2011","journal-title":"International Journal of Oncology"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e41948","article-title":"Reciprocal regulation between DNMT3A\/3B and microRNAs miRs-299-3p\/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer","volume":"11","author":"Ganapathy","year":"2025","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4161\/epi.5.2.10778","article-title":"Epigenetic regulation of androgen receptor signaling in prostate cancer","volume":"5","author":"Gao","year":"2010","journal-title":"Epigenetics: Official Journal of the DNA Methylation Society"},{"issue":"9","key":"10.1016\/bs.vh.2025.04.001_bib35","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.vh.2025.04.001_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Annual Review of Medicine"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib38","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2174\/13816128113199990516","article-title":"Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells","volume":"20","author":"Gra\u00e7a","year":"2014","journal-title":"Current Pharmaceutical Design"},{"issue":"7","key":"10.1016\/bs.vh.2025.04.001_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/pros.20748","article-title":"Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells","volume":"68","author":"Gravina","year":"2008","journal-title":"The Prostate"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib40","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pros.21151","article-title":"5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors","volume":"70","author":"Gravina","year":"2010","journal-title":"The Prostate"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/ERC-12-0240","article-title":"PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer","volume":"20","author":"Gravina","year":"2013","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/bs.vh.2025.04.001_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.110913","article-title":"Developmental programming: Prenatal testosterone-induced changes in epigenetic modulators and gene expression in metabolic tissues of female sheep","volume":"514","author":"Guo","year":"2020","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: An overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocrine Reviews"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"13","key":"10.1016\/bs.vh.2025.04.001_bib45","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1111\/jcmm.15281","article-title":"CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action","volume":"24","author":"Hu","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ijms23010392","article-title":"The crosstalk of long non-coding RNA and microRNA in castration-resistant and neuroendocrine prostate cancer: Their interaction and clinical importance","volume":"23","author":"Hu","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"10.1016\/bs.vh.2025.04.001_bib47","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pros.23832","article-title":"Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75","volume":"79","author":"Hu","year":"2019","journal-title":"The Prostate"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"The Journal of Urology"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib49","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/nu12041010","article-title":"Flavonoids as epigenetic modulators for prostate cancer prevention","volume":"12","author":"Izzo","year":"2020","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib50","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/nu10111784","article-title":"Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines","volume":"10","author":"Jang","year":"2018","journal-title":"Nutrients"},{"issue":"35","key":"10.1016\/bs.vh.2025.04.001_bib51","doi-asserted-by":"crossref","first-page":"56767","DOI":"10.18632\/oncotarget.10790","article-title":"Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells","volume":"7","author":"Jeong","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"issue":"10","key":"10.1016\/bs.vh.2025.04.001_bib53","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/cancers15102763","article-title":"DNA methyltransferase 1 targeting using guadecitabine inhibits prostate cancer growth by an apoptosis-independent pathway","volume":"15","author":"Karan","year":"2023","journal-title":"Cancers"},{"issue":"107","key":"10.1016\/bs.vh.2025.04.001_bib54","doi-asserted-by":"crossref","first-page":"ra8","DOI":"10.1126\/scisignal.2000568","article-title":"Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor","volume":"3","author":"Kino","year":"2010","journal-title":"Science Signaling"},{"issue":"7","key":"10.1016\/bs.vh.2025.04.001_bib55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41571-018-0028-9","article-title":"Author correction: Analysis of DNA methylation in cancer: Location revisited","volume":"15","author":"Koch","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.vh.2025.04.001_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2020.11.039","article-title":"Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer","volume":"504","author":"Kumar","year":"2021","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2021.03.005","article-title":"Recent advances in epigenetic biomarkers and epigenetic targeting in prostate cancer","volume":"80","author":"Kumaraswamy","year":"2021","journal-title":"European Urology"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/frne.2001.0216","article-title":"DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology","volume":"22","author":"Labrie","year":"2001","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/bs.vh.2025.04.001_bib59","doi-asserted-by":"crossref","first-page":"1244655","DOI":"10.3389\/fphar.2023.1244655","article-title":"YIV-818-A: A novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy","volume":"14","author":"Lam","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib60","first-page":"69","article-title":"EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity","volume":"30","author":"Lee","year":"2012","journal-title":"International Journal of Molecular Medicine"},{"issue":"30","key":"10.1016\/bs.vh.2025.04.001_bib61","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","article-title":"LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer","volume":"35","author":"Li","year":"2025","journal-title":"Cell Research"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jnci\/dji010","article-title":"Epigenetic changes in prostate cancer: Implication for diagnosis and treatment","volume":"97","author":"Li","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: Molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.21247","article-title":"Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth","volume":"71","author":"Lin","year":"2011","journal-title":"The Prostate"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/aja.aja_63_20","article-title":"Methylated CpG dinucleotides in the 5-\u03b1 reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients","volume":"23","author":"Lin","year":"2021","journal-title":"Asian Journal of Andrology"},{"issue":"4850","key":"10.1016\/bs.vh.2025.04.001_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/science.3353727","article-title":"Cloning of human androgen receptor complementary DNA and localization to the X chromosome","volume":"240","author":"Lubahn","year":"1988","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.vh.2025.04.001_bib68","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","article-title":"ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer","volume":"31","author":"Mahajan","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib69","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nm.3830","article-title":"Targeting the MLL complex in castration-resistant prostate cancer","volume":"21","author":"Malik","year":"2015","journal-title":"Nature Medicine"},{"issue":"207","key":"10.1016\/bs.vh.2025.04.001_bib70","first-page":"81","article-title":"An inapparent infection with a probable picornavirus in several stocks of laboratory reared and naturally occurring populations of Dacus oleae Gmel. Pupae in Greece","volume":"51","author":"Manousis","year":"1987","journal-title":"Microbios"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1258\/acb.2012.012159","article-title":"Clinical biochemistry of dihydrotestosterone","volume":"50","author":"Marchetti","year":"2013","journal-title":"Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"},{"issue":"7","key":"10.1016\/bs.vh.2025.04.001_bib72","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tig.2022.03.010","article-title":"DNA methylation: A historical perspective","volume":"38","author":"Mattei","year":"2022","journal-title":"Trends in Genetics: TIG"},{"key":"10.1016\/bs.vh.2025.04.001_bib73","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddl046","article-title":"Non-coding RNA","volume":"15 Spec No 1","author":"Mattick","year":"2006","journal-title":"Human Molecular Genetics"},{"issue":"6","key":"10.1016\/bs.vh.2025.04.001_bib74","first-page":"386","article-title":"Studying the classics","volume":"11","author":"McCarthy","year":"2011","journal-title":"Nature Reviews. Cancer"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib75","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrg2521","article-title":"Long non-coding RNAs: Insights into functions","volume":"10","author":"Mercer","year":"2009","journal-title":"Nature Reviews. Genetics"},{"issue":"10","key":"10.1016\/bs.vh.2025.04.001_bib76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/biomedicines8100422","article-title":"The androgen receptor in prostate cancer: Effect of structure, ligands and spliced variants on therapy","volume":"8","author":"Messner","year":"2020","journal-title":"Biomedicines"},{"issue":"7057","key":"10.1016\/bs.vh.2025.04.001_bib77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib78","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/cas.13352","article-title":"Long non-coding RNAs and prostate cancer","volume":"108","author":"Misawa","year":"2017","journal-title":"Cancer Science"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/edrv-8-1-1","article-title":"Biological actions of androgens","volume":"8","author":"Mooradian","year":"1987","journal-title":"Endocrine Reviews"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib81","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ecl.2011.05.013","article-title":"New hormonal therapies for castration-resistant prostate cancer","volume":"40","author":"Mostaghel","year":"2011","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"39","key":"10.1016\/bs.vh.2025.04.001_bib82","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","article-title":"Going beyond polycomb: EZH2 functions in prostate cancer","volume":"40","author":"Park","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib83","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.biopha.2013.01.006","article-title":"A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells","volume":"67","author":"Patra","year":"2013","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.vh.2025.04.001_bib84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-4598-10-94","article-title":"Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer","volume":"10","author":"Pellacani","year":"2011","journal-title":"Molecular Cancer"},{"key":"10.1016\/bs.vh.2025.04.001_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.948217","article-title":"Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer","volume":"10","author":"Pramanik","year":"2022","journal-title":"Frontiers in Chemistry"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib87","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Molecular Oncology"},{"issue":"29","key":"10.1016\/bs.vh.2025.04.001_bib89","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/onc.2015.444","article-title":"HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer","volume":"35","author":"Ruscetti","year":"2016","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/bs.vh.2025.04.001_bib90","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/0008-5472.CAN-08-0203","article-title":"OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model","volume":"68","author":"Sargeant","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/bs.vh.2025.04.001_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1083486","article-title":"The epigenetic function of androgen receptor in prostate cancer progression","volume":"11","author":"Sawada","year":"2023","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PLoS Biology"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib93","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10637-010-9503-6","article-title":"Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies","volume":"30","author":"Schneider","year":"2012","journal-title":"Investigational New Drugs"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/pcan.2013.28","article-title":"Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer","volume":"16","author":"Schweizer","year":"2013","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"7046","key":"10.1016\/bs.vh.2025.04.001_bib95","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.vh.2025.04.001_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2011.02.016","article-title":"Understanding extranuclear (nongenomic) androgen signaling: What a frog oocyte can tell us about human biology","author":"Sen","year":"2011","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","article-title":"The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","volume":"23","author":"Sharma","year":"2013","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib98","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/mc.22433","article-title":"Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor \u03b2","volume":"55","author":"Sharma","year":"2016","journal-title":"Molecular Carcinogenesis"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib99","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1208\/s12248-011-9300-y","article-title":"Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells","volume":"13","author":"Shu","year":"2011","journal-title":"The AAPS Journal"},{"key":"10.1016\/bs.vh.2025.04.001_bib100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.semcancer.2021.03.013","article-title":"Current paradigms in epigenetic anticancer therapeutics and future challenges","volume":"83","author":"Singh","year":"2022","journal-title":"Seminars in Cancer Biology"},{"key":"10.1016\/bs.vh.2025.04.001_bib101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/bs.vh.2022.11.007","article-title":"Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer","volume":"122","author":"Singh","year":"2023","journal-title":"Vitamins and Hormones"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib102","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/1535-7163.MCT-07-0221","article-title":"Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro","volume":"6","author":"Sonnemann","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"issue":"6330","key":"10.1016\/bs.vh.2025.04.001_bib103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","article-title":"Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy","volume":"352","author":"Spada","year":"1991","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib104","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1101\/gad.12.5.599","article-title":"Histone acetylation and transcriptional regulatory mechanisms","volume":"12","author":"Struhl","year":"1998","journal-title":"Genes & Development"},{"issue":"4","key":"10.1016\/bs.vh.2025.04.001_bib105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/aps.2016.139","article-title":"Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration","volume":"38","author":"Sun","year":"2017","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/bs.vh.2025.04.001_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.573820","article-title":"Tumor suppressive maspin-sensitized prostate cancer to drug treatment through negative regulating androgen receptor expression","volume":"8","author":"Tang","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/bs.vh.2025.04.001_bib108","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygcen.2017.04.016","article-title":"ZIP9, a novel membrane androgen receptor and zinc transporter protein","volume":"257","author":"Thomas","year":"2018","journal-title":"General and Comparative Endocrinology"},{"issue":"20","key":"10.1016\/bs.vh.2025.04.001_bib109","doi-asserted-by":"crossref","first-page":"9044","DOI":"10.1021\/jo301534b","article-title":"Discovery and characterization of NK13650s, naturally occurring p300-selective histone acetyltransferase inhibitors","volume":"77","author":"Tohyama","year":"2012","journal-title":"The Journal of Organic Chemistry"},{"issue":"9","key":"10.1016\/bs.vh.2025.04.001_bib110","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.humpath.2013.01.022","article-title":"Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence","volume":"44","author":"Tsourlakis","year":"2013","journal-title":"Human Pathology"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17501911.2024.2430169","article-title":"Cancer epigenetic therapy: Recent advances, challenges, and emerging opportunities","volume":"17","author":"Vatapalli","year":"2025","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib112","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.20673","article-title":"DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines","volume":"68","author":"Walton","year":"2008","journal-title":"The Prostate"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172137","article-title":"PP2A inhibition causes synthetic lethality in BRCA2-mutated prostate cancer models via spindle assembly checkpoint reactivation","volume":"134","author":"Wang","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib114","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2015.09.164","article-title":"Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo","volume":"467","author":"Wang","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib116","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.21873\/anticanres.14226","article-title":"Androgen-induced epigenetic profiles of polycomb and trithorax genes in prostate cancer cells","volume":"40","author":"Wang","year":"2020","journal-title":"Anticancer Research"},{"issue":"8","key":"10.1016\/bs.vh.2025.04.001_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256468","article-title":"Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines","volume":"16","author":"Weiner","year":"2021","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/bs.vh.2025.04.001_bib118","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s11154-022-09730-z","article-title":"Androgens, aging, and prostate health","volume":"23","author":"Wel\u00e9n","year":"2022","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"issue":"5","key":"10.1016\/bs.vh.2025.04.001_bib119","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/edrv.20.5.0377","article-title":"The role of androgens in male gender role behavior","volume":"20","author":"Wilson","year":"1999","journal-title":"Endocrine Reviews"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ncb1546","article-title":"Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression","volume":"9","author":"Wissmann","year":"2007","journal-title":"Nature Cell Biology"},{"issue":"3","key":"10.1016\/bs.vh.2025.04.001_bib121","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1208\/s12248-013-9493-3","article-title":"Epigenetic modifications of Nrf2 by 3,3\u2019-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors","volume":"15","author":"Wu","year":"2013","journal-title":"The AAPS Journal"},{"issue":"8","key":"10.1016\/bs.vh.2025.04.001_bib122","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/me.2014-1042","article-title":"Early embryonic androgen exposure induces transgenerational epigenetic and metabolic changes","volume":"28","author":"Xu","year":"2014","journal-title":"Molecular Endocrinology (Baltimore, Md.)"},{"issue":"722","key":"10.1016\/bs.vh.2025.04.001_bib123","doi-asserted-by":"crossref","first-page":"eadf6732","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Science Translational Medicine"},{"issue":"7464","key":"10.1016\/bs.vh.2025.04.001_bib124","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature12451","article-title":"lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs","volume":"500","author":"Yang","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12964-019-0457-9","article-title":"SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability","volume":"17","author":"Yang","year":"2019","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"8","key":"10.1016\/bs.vh.2025.04.001_bib126","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbagrm.2019.05.005","article-title":"The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis","volume":"1862","author":"Yang","year":"2019","journal-title":"Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms"},{"issue":"21","key":"10.1016\/bs.vh.2025.04.001_bib127","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","article-title":"DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity","volume":"68","author":"Yegnasubramanian","year":"2008","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.vh.2025.04.001_bib128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.canlet.2016.01.036","article-title":"DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers","volume":"373","author":"Yen","year":"2016","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"issue":"11","key":"10.1016\/bs.vh.2025.04.001_bib130","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/2767-9764.CRC-23-0250","article-title":"Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers","volume":"3","author":"Zhang","year":"2023","journal-title":"Cancer Research Communications"},{"issue":"6","key":"10.1016\/bs.vh.2025.04.001_bib131","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41588-018-0120-1","article-title":"Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression","volume":"50","author":"Zhang","year":"2018","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1016\/bs.vh.2025.04.001_bib132","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/01635581.2019.1619783","article-title":"Sulforaphane bioavailability and chemopreventive activity in men presenting for biopsy of the prostate gland: A randomized controlled trial","volume":"72","author":"Zhang","year":"2020","journal-title":"Nutrition and Cancer"},{"issue":"8","key":"10.1016\/bs.vh.2025.04.001_bib133","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1016\/bs.vh.2025.04.001_bib134","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/ijbs.8389","article-title":"Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer","volume":"10","author":"Zhao","year":"2014","journal-title":"International Journal of Biological Sciences"},{"issue":"12","key":"10.1016\/bs.vh.2025.04.001_bib135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrendo.2009.212","article-title":"Testosterone deficiency, insulin resistance and the metabolic syndrome","volume":"5","author":"Zitzmann","year":"2009","journal-title":"Nature Reviews Endocrinology"}],"container-title":["Vitamins and Hormones","Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672925000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672925000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:43:05Z","timestamp":1755614585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672925000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443295485"],"references-count":135,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2025.04.001","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}